# Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors

> **NCT07399769** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen University General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue)

## Interventions

- **COMBINATION_PRODUCT:** CAR-T

## Key facts

- **NCT ID:** NCT07399769
- **Lead sponsor:** Shenzhen University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2027-01-30
- **Final completion:** 2027-01-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07399769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07399769, "Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07399769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*